Výsledky vyhledávání - "Leathia Fiorino"

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab

Autor: Tiffany Patterson, Nicole S. Croteau, Doran Ksienski, Sarah Irons, Deepu Alex, Angela Chan, Ashley T. Freeman, Zia Poonja, Leathia Fiorino, Elaine S. Wai, Melissa Clarkson, David Fenton, Mary Lesperance

Publikováno v: Transl Lung Cancer Res

BACKGROUND: We investigated the association of peripheral blood inflammatory markers with overall survival (OS) in pembrolizumab treated advanced non-small cell lung cancer (aNSCLC) patients with programmed death ligand 1 (PD-L1) expression ≥50%. C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161445869bb9d1507eb651786fe253b8
https://doi.org/10.21037/tlcr-20-541

Zobrazit plný text záznamu

Treatment of Non-Small-Cell Lung Cancer after Progression on Nivolumab or Pembrolizumab

Autor: Nicole S. Croteau, Sarah Irons, David Fenton, Leathia Fiorino, Elaine S. Wai, G. Geller, Mary Lesperance, E.G. Brooks, Doran Ksienski, Ashley T. Freeman, Zia Poonja

Publikováno v: Curr Oncol
Current Oncology
Volume 27
Issue 2
Pages 5495-82

Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238bf128e8e9921ed6a66ee8fd11c757
https://doi.org/10.3747/co.27.5495

Zobrazit plný text záznamu

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice

Autor: David Fenton, Ashley T. Freeman, Zia Poonja, Elaine S. Wai, G. Geller, Doran Ksienski, E. Brooks, Sarah Irons, Mary Lesperance, Nicole S. Croteau, Angela Chan, Leathia Fiorino

Publikováno v: Lung Cancer. 133:110-116

While pembrolizumab improves overall survival (OS) in a subset of advanced nonsmall cell lung cancer (aNSCLC) patients (pts) in clinical trials, individuals with poor Eastern Cooperative Oncology Group performance status (ECOG PS) were excluded. Furt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de395f0b525e45b26b7dad114d964266
https://doi.org/10.1016/j.lungcan.2019.05.005

Zobrazit plný text záznamu

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab

Autor: Nicole S. Croteau, Leathia Fiorino, Tiffany Patterson, Mary Lesperance, David Fenton, Angela Chan, Sarah Irons, Elaine S. Wai, Ashley T. Freeman, Zia Poonja, Doran Ksienski

Publikováno v: Journal of geriatric oncology. 11(5)

Objectives To explore the association of age with development of immune related adverse events (irAE) and survival in patients with advanced nonsmall cell lung cancer (aNSCLC) receiving programmed cell death 1 antibodies (PD-1 Ab) outside of clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141ac323558bc581238c01903853ccd9
https://pubmed.ncbi.nlm.nih.gov/31937494

Zobrazit plný text záznamu

Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience

Autor: Anna V. Tinker, Helena O’Dwyer, Aalok Kumar, Leathia Fiorino

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 28(8)

ObjectiveWe conducted a population-based analysis of patient outcomes following treatment with bevacizumab and platinum–based chemotherapy for metastatic, recurrent, or persistent cervical carcinoma.MethodsEligible cases were identified using the B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155656d77fe1c6a8060c400a58e54d38
https://pubmed.ncbi.nlm.nih.gov/30247250

Zobrazit plný text záznamu

Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice

Autor: Nicole S. Croteau, Dave Fenton, Mary Lesperance, Ashley T. Freeman, Doran Ksienski, Zia Poonja, E. Brooks, G. Geller, Elaine S. Wai, Angela Chan, Leathia Fiorino, Sarah Irons

Publikováno v: Journal of Clinical Oncology. 37:e20506-e20506

e20506 Background: In clinical trials, Pem improves overall survival (OS) compared to chemotherapy in a subset of patients (pts) with aNSCLC. Immune related adverse events (irAE) have correlated with improved OS in some studies. We explored efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6fdbb4611fad2f86aea85bcfeae8fa32
https://doi.org/10.1200/jco.2019.37.15_suppl.e20506

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání